Targeting protein biotinylation enhances tuberculosis chemotherapy

Area of Science:

• Microbiology and Infectious Diseases
• Drug Discovery and Development
• Biochemistry

Background:

• Tuberculosis (TB) treatment relies on drug combinations, but drug resistance threatens efficacy.
• Novel drug targets are needed to replace or augment components of current TB chemotherapy.
• Bacterial biotin protein ligase (BPL) is essential for protein biotinylation in Mycobacterium tuberculosis (Mtb).

Purpose of the Study:

• To investigate the potential of bacterial biotin protein ligase (BPL) as a novel drug target for tuberculosis (TB).
• To evaluate the efficacy of inhibiting BPL against Mycobacterium tuberculosis (Mtb) in vitro and in vivo.
• To assess whether BPL inhibition can potentiate the activity of existing first-line TB drugs.

Main Methods:

• Chemical inhibition of Mtb BPL using the specific inhibitor Bio-AMS.
• Genetic silencing of BPL in Mtb to assess its role in infection.
• In vivo studies in mice to evaluate the efficacy of BPL inhibition and its combination with rifampicin and ethambutol.

Main Results:

• Chemical inhibition of BPL with Bio-AMS demonstrated bactericidal activity against Mtb.
• Genetic silencing of BPL led to efficient elimination of Mtb during both acute and chronic infections in mice.
• Partial BPL inactivation enhanced the potency of rifampicin and ethambutol, and accelerated Mtb clearance by rifampicin.

Conclusions:

• Bacterial biotin protein ligase (BPL) is a validated and essential drug target for Mycobacterium tuberculosis (Mtb).
• Inhibition of BPL presents a promising strategy for developing new anti-TB drugs.
• BPL-targeting agents could serve as frontline therapies or potentiate existing TB treatments.